CRISPR Therapeutics shareholders reject authorized capital increase; approve stock plan amendment

CRISPR Therapeutics AG

Proposal 10 to adjust authorized share capital and extend date for capital increase was not approved (37.0M for, 18.8M against).
Amendment to 2018 Stock Plan approved, adding 1.7M common shares for issuance under the plan.
Maria Fardis, Ph.D. elected as new board member; all nine incumbent directors re-elected.
Binding advisory votes on executive compensation approved; frequency of say-on-pay set at one year.
All other proposals passed, including re-election of auditors and independent voting representative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.